Current Report Filing (8-k)
12 Februar 2018 - 11:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 12, 2018
ARDELYX, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36485
|
|
26-1303944
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
34175 Ardenwood Blvd., Suite 200
Fremont, CA 94555
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code:
(510) 745-1700
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
On February 12, 2018, Ardelyx, Inc. (the Company) announced that Jeremy
Caldwell, Ph.D., the Companys Chief Scientific Officer, will be leaving the Company, effective February 16, 2018, to pursue a position as chief executive officer of an early-stage private biotechnology company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: February 12, 2018
|
|
|
|
ARDELYX, INC.
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Mark Kaufmann
|
|
|
|
|
|
|
|
|
Mark Kaufmann
|
|
|
|
|
|
|
|
|
Chief Financial Officer
|
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024